M.D. Anderson Cancer Center
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Primary Objectives * Cohort 1: To evaluate the safety and tolerability of BMS-986504 in combination with neoadjuvant/adjuvant chemotherapy and as maintenance therapy in participants with resectable/borderline resectable PDAC. Major pathological response (MPR) and incidence, severity and duration of pre- and post-operative complications (e.g. delay of surgery, inability to get surgery, type and rate of postoperative complications \[like pancreatic fistula\], rate of resection for borderline participants) will be evaluated. * Cohorts 2 and 3: To evaluate the safety, tolerability and efficacy of…
Eligibility Criteria * Age ≥18 years. * Homozygous MTAP deletion detected by NGS. Test can be performed on an archival tissue collected within 6 months from study enrollment and on blood samples. * ECOG performance status 0-1. * Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) * Adequate organ and marrow function as defined below * Hemoglobin ≥9.0 g/dL with no packed red blood cell transfusions in the past 7 days. * Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L. * Platelet count ≥100 x 10⁹/L with no platelet transfusions in the past 7 days. * Total bil…
Given by po
Given by IV
Given by IV
Given by iv
Arctuva estimate
Verify or correct the compensation shown for this listing.